BioAge Labs, Inc. (BIOA)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	22.45	19.16	14.51	9.45
Research & Development	59.04	59.04	33.89	30.52
Operating Expenses	81.49	78.19	48.4	39.97
Operating Income	-81.83	-78.19	-48.4	-39.97
Interest Expense	-1.41	-2.37	-7.79	-0.24
Interest & Investment Income	12.05	9.63	2.43	0.47
EBT Excluding Unusual Items	-71.12	-70.93	-53.76	-39.75
Other Unusual Items	0.07	-0.18	-10.09	0.02
Pretax Income	-71.05	-71.11	-63.85	-39.72
Net Income	-71.05	-71.11	-63.85	-39.72
Net Income to Common	-71.05	-71.11	-63.85	-39.72
Shares Outstanding (Basic)	19	11	2	2
Shares Outstanding (Diluted)	19	11	2	2
Shares Change (YoY)	1051.87%	541.23%	0.06%	-
EPS (Basic)	-3.69	-6.63	-38.17	-23.76
EPS (Diluted)	-3.69	-6.63	-38.17	-23.76
Free Cash Flow	-54.01	-51.89	-37.53	-36.28
Free Cash Flow Per Share	-2.80	-4.84	-22.43	-21.70
EBITDA	-81.66	-78.03	-48.24	-39.84
D&A For EBITDA	0.17	0.17	0.16	0.13
EBIT	-81.83	-78.19	-48.4	-39.97

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q